HIV Pre-Exposure Prophylaxis (PrEP) Timing
PrEP should be initiated immediately (same-day/rapid start) if an HIV test from within the past 7 days is negative and there are no signs or symptoms of acute HIV infection, without waiting for additional laboratory results. 1
Baseline Testing Requirements
The primary goal before initiating PrEP is to exclude undiagnosed HIV infection. Here's the algorithmic approach:
If HIV Test Available Within 7 Days:
- Start PrEP same-day if combined HIV antibody/antigen test is negative and patient has no symptoms of acute HIV infection 1, 2
- Additional safety labs (renal function, hepatitis screening, STI testing) can be pending—do not delay PrEP initiation while awaiting these results 1
If No Recent HIV Test:
- Perform rapid point-of-care HIV antibody test at the visit
- Start PrEP immediately if negative 2
- Also send laboratory-based HIV antibody/antigen test for confirmation 2
- PrEP may be initiated remotely once baseline HIV tests are confirmed negative 1
If Acute HIV Infection Suspected:
- Withhold PrEP and perform HIV RNA testing 2
- If clinical suspicion is high, initiate full antiretroviral therapy (early treatment) instead 2
Special Timing Considerations
Recent High-Risk Exposure (Within 72 Hours):
Use post-exposure prophylaxis (PEP) instead of PrEP:
- Prescribe 3-drug PEP regimen for 28 days 1, 2
- Transition seamlessly to PrEP after PEP completion if HIV test (ideally antigen/antibody AND RNA) is negative 1
Exposure >72 Hours Ago:
- Initiate PrEP according to standard rapid-start protocol 2
Oral PrEP Timing Specifics
Daily Dosing (TDF/FTC or TAF/FTC):
- Prescribe maximum 30-day supply initially 2
- Switch to 90-day supplies after first month 2
- Protection achieved after 7 days of daily dosing for receptive anal sex; 20 days for receptive vaginal sex
On-Demand Dosing (2-1-1 for TDF/FTC):
- Only for cisgender men having planned receptive anal sex 1
- Double dose 2-24 hours before sex
- Single dose 24 hours after first dose
- Single dose 48 hours after first dose
- Not validated for vaginal exposures or injection drug use 1
Injectable PrEP (Long-Acting Cabotegravir) Timing
Initiation Protocol:
- Oral lead-in (4-5 weeks) is optional 1
- Recommended only for those with severe atopic histories or who request it 1
- Not recommended for those with adherence challenges to daily pills 1
Overlap Strategy for Maximum Protection:
- Continue oral PrEP for 7 days after first injection 1
- If transitioning from oral cabotegravir lead-in: use oral cabotegravir tablets for overlap 1
- If starting fresh or from tenofovir-based PrEP: use appropriate tenofovir-based regimen for overlap 1
Injection Schedule:
- First two injections: 4 weeks apart
- Subsequent injections: 8 weeks apart 1
- Patients should have 1-month supply of oral PrEP on hand for injection delays ≥7 days 1
Follow-Up Testing Timeline
First Month:
Ongoing Monitoring:
- HIV testing every 3 months (quarterly) 2
- Creatinine clearance at first quarterly visit, then annually (unless high-risk for kidney injury) 2
- For patients >50 years, baseline CrCl <90 mL/min, or comorbidities (diabetes, hypertension): monitor renal function every 3-6 months 2
Critical Pitfalls to Avoid
Do not delay PrEP initiation for non-HIV laboratory results. Any delay represents a missed opportunity for HIV prevention 1. The 2025 IAS-USA guidelines explicitly state this is the most important timing principle.
Do not use bone density scans as a barrier to starting tenofovir-based PrEP—they are not necessary before initiation 1.
Do not confuse PrEP with PEP timing. The 72-hour window is critical: exposures within 72 hours require PEP, not PrEP 1, 2.
For transgender women using gender-affirming hormone therapy on 2-1-1 dosing, administer TDF/FTC with food to ensure adequate rectal tissue drug concentrations 1.
Research data show that in real-world practice, only 35% of PrEP initiators receive appropriate baseline HIV testing 3, highlighting the gap between guidelines and implementation. However, the guideline recommendation remains clear: rapid initiation with appropriate HIV testing is the standard of care.